GLPBio

Aureobasidin A

Catalog No.: GC62854Purity:>99.00%
COASDSData Sheet
Aureobasidin A (Basifungin), ein zyklisches Depsipetid, ist ein antimykotisches Antibiotikum.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.

Aureobasidin A
Cas No.: 127785-64-2
1 mgIn Stock
$135.00
1
5 mgIn Stock
$351.00
1
10 mgIn Stock
$522.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

Aureobasidin A is an orally active cyclic peptide antibiotic[1]. Aureobasidin A is an inhibitor of inositol phosphorylating ceramide synthase AUR1[2]. Aureobasidin A has antifungal and antiparasitic activities[3, 4].

In vitro, Aureobasidin A (20ng/mL) treatment of Candida albicans SC5314 for 24h completely inhibited the growth of the strain[5]. Aureobasidin A (5, 10μg/mL) treated with Toxoplasma gondii tachyzoites for 24h significantly inhibited the proliferation of Toxoplasma gondii tachyzoites[6].

In vivo, Aureobasidin A (20, 40mg/kg) was used orally and subcutaneously to treat mice with systemic Candida infection, producing good therapeutic effects, which were superior to fluconazole and amphotericin B[7].

References:
[1] Teymuri M, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans[J]. Bioorganic & Medicinal Chemistry Letters, 2021, 41: 128013.
[2] Katsuki Y, Yamaguchi Y, Tani M. Overexpression of PDR16 confers resistance to complex sphingolipid biosynthesis inhibitor aureobasidin A in yeast Saccharomyces cerevisiae[J]. FEMS microbiology letters, 2018, 365(3): fnx255.
[3] Alimehr S, Shams-Ghahfarokhi M, Razzaghi Abyaneh M. Antifungal activity of Aureobasidin a in combination with Fluconazole against fluconazole-resistant Candida albicans[J]. Infection Epidemiology and Microbiology, 2020, 6(4): 285-291.
[4] Tanaka A K, Valero V B, Takahashi H K, et al. Inhibition of Leishmania (Leishmania) amazonensis growth and infectivity by aureobasidin A[J]. Journal of Antimicrobial Chemotherapy, 2007, 59(3): 487-492.
[5] Zheng L, Xu Y, Dong Y, et al. Chromosome 1 trisomy confers resistance to aureobasidin A in Candida albicans[J]. Frontiers in Microbiology, 2023, 14: 1128160.
[6] Alqaisi A Q I, Mbekeani A J, Llorens M B, et al. The antifungal Aureobasidin A and an analogue are active against the protozoan parasite Toxoplasma gondii but do not inhibit sphingolipid biosynthesis[J]. Parasitology, 2018, 145(2): 148-155.
[7] TAKESAKO K, KURODA H, INOUE T, et al. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic[J]. The Journal of antibiotics, 1993, 46(9): 1414-1420.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

C. albicans lab strain SC5314

Preparation Method

C. albicans lab strain SC5314 was grown in YPD broth or on YPD plates supplemented with 0-20ng/mL Aureobasidin A. Optical density at 595nm was measured every 15min for 24h at 37°C using a Tecan plate reader. 3μL of 10-fold serial dilutions were spotted on YPD plates. The plates were incubated at 37°C for 48h then photographed.

Reaction Conditions

0-20ng/mL; 24h、48h

Applications

In the liquid medium, growth in the presence of 5ng/mL or 10ng/mL of Aureobasidin A did not significantly inhibit growth. 20ng/mL of Aureobasidin A completely inhibited growth. On the plates, growth was also inhibited by 20ng/ml of Aureobasidin A.

Animal experiment [2]:

Animal models

ICR mice

Preparation Method

Groups of mice were treated with Aureobasidin A, Fluconazole or Amphotericin B. Aureobasidin A or Fuconazole was administered orally once daily from day-0 to -6 at the dose of 20mg/kg and from day-3 to -9 at the dose of 40mg/kg. Amphotericin B was given subcutaneously once daily from day-3 to -9 at the dose of 5mg/kg. On day-0 and -4, -7, -10, -14, and -21 after infection, some mice in each group were sacrificed and their kidneys were removed aseptically. The removed kidneys were sectioned through the middle and the exposed surface was stamped on SD agar plates for inoculation. All of the plates were incubated at 30°C for 2 days and the number of visibly growing colonies of C. albicans were Whenfive counted.

Dosage form

20、40mg/kg; p.o.

Applications

Aureobasidin A shows low toxicity and good efficacy against murine candidiasis. Aureobasidin A also prolongs survival days of infected mice by oral treatment, even when the treatment was started after completion of infection.

References:
[1]Zheng L, Xu Y, Dong Y, et al. Chromosome 1 trisomy confers resistance to aureobasidin A in Candida albicans[J]. Frontiers in Microbiology, 2023, 14: 1128160.
[2]TAKESAKO K, KURODA H, INOUE T, et al. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic[J]. The Journal of antibiotics, 1993, 46(9): 1414-1420.

Produktdokumente (Product Documents)

Purity:>99.00%Appearance:A solid
COASDSData Sheet

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
127785-64-2
Summenformel
C60H92N8O11
Molekulargewicht
1101.42
Löslichkeit
DMSO : 100 mg/mL (90.79 mM; Need ultrasonic)
Lagerung
Store at -20°C, protect from light
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for Aureobasidin A

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%